> top > docs > PMC:7228307 > spans > 2484-3199 > annotations

PMC:7228307 / 2484-3199 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
35 312-333 Disease denotes inflammatory diseases MESH:D007249
36 346-353 Disease denotes cancers MESH:D009369
37 384-396 Disease denotes malignancies MESH:D009369

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T8 312-333 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T31 233-234 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T32 523-526 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T9 492-497 Chemical denotes sales http://purl.obolibrary.org/obo/CHEBI_24866
T10 527-532 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T13 252-260 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T14 325-333 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes
35 312-333 Disease denotes inflammatory diseases MESH:D007249
36 346-353 Disease denotes cancers MESH:D009369
37 384-396 Disease denotes malignancies MESH:D009369

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T18 0-135 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 136-261 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 262-715 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T6 312-333 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T18 0-135 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 136-261 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 262-715 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1